• / Free eNewsletters & Magazine
  • / My Account
Home>XIFIN Launches Next-Generation Sequencing Module; Expands Genomics-Based LIS Workflow

XIFIN Launches Next-Generation Sequencing Module; Expands Genomics-Based LIS Workflow

XIFIN Launches Next-Generation Sequencing Module; Expands Genomics-Based LIS Workflow


XIFIN Launches Next-Generation Sequencing Module; Expands Genomics-Based LIS Workflow

NGS Supports Molecular Business Growth, Laboratory Sequencing Operations and Precision Medicine

CAP17 Booth 220 -- XIFIN, Inc., the healthcare information technology company revolutionizing the business of healthcare diagnostics, today announced that it has expanded its laboratory information system, XIFIN LIS Anywhere, with the launch of a next-generation sequencing module to provide advanced workflow functionality for laboratory sequencing operations and precision medicine. XIFIN LIS Anywhere for NGS will be showcased at the College of American Pathologist’s CAP17 Meeting, being held Oct. 8-11 in National Harbor, Maryland.

XIFIN LIS Anywhere is an advanced laboratory information system that includes robust solutions for anatomic pathology, molecular diagnostics and genomics, and clinical and toxicology. The diagnostic platform supports XIFIN ProNet, a collaborative clinical data management solution that facilitates cloud-based digital pathology as well as physician collaboration through the exchange of key images, data and reports.

The NGS module expands XIFIN’s suite of genomics-based LIS workflow tools to help labs grow molecular lines of business, drive adoption of sequencing tests, and improve the genomics workflow for better patient outcomes and maximum return on investment.

NGS has transformed the genomics and molecular diagnostics landscape. According to the Next Generation Sequencing Market Report published by Allied Market Research, the global NGS market is expected to reach $12.8 billion by 2022. Technological advancements in NGS platforms, increasing applications, and unprecedented adoption of NGS among research laboratories and academic institutions are driving the growth of the market.

“XIFIN continues to invest in genomics-based LIS and genetic analysis solutions — including pharmacogenomics testing and interpretation, polymerase chain reaction methods, telegenetic counseling services, and our newly launched next-generation sequencing module — to help innovative labs grow new business lines and support precision medicine initiatives,” stated Lâle White, CEO of XIFIN. “In addition, XIFIN ProNet enables precise tracking of patient response to therapy lines by combining clinical narratives with patient level data, imaging and NGS results.”

XIFIN LIS Anywhere for NGS provides intuitive cloud-based workflow management to support the sequencing operations of genomic laboratories for commercial testing. The end-to-end workflow solution enables laboratories to drive growth of business lines by improving sequencing operations through efficient wet lab management, extending the AP module for TC/PC splits and facilitating cloud-based digital images as well as physician collaboration. XIFIN LIS Anywhere for NGS improves sequencing efficiencies through the following capabilities:

©2017 Morningstar Advisor. All right reserved.